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ABSTRACT
Objective: Acquired immunodeficiency syndrome (AIDS) was first identified in the Western world in 1981. Since then, AIDS has been increasingly 
wide spreading, its rapid worldwide dissemination brought about by modern mass tourism. Isatin (1 H-indole-2, 3-Dione), an endogenous compound 
identified in many organisms, shows a wide range of biological activities. In view of the above details, we wish to report the synthesis and evaluation 
of novel isatin analogs, as promising anti-human immunodeficiency (HIV) agents.
Methods: A series of novel isatin analogs (3a-3p) were synthesized, and their chemical structures were confirmed by nuclear magnetic resonance:1H, 
13C, ESI-MS spectral data, and CHNS.
Results: The compounds were evaluated as inhibitors of HIV type-1 in MT-4 cell cultures. Of these sixteen compounds, only 5 compounds showed 
potent anti-HIV activity.
Conclusion: Evaluation of compound properties in silico showed that they possess significant drug-like characteristics.
Keywords: Isatin analogs, Synthesis, Human immunodeficiency virus, Biological screening, Absorption, distribution, metabolism and elimination.
INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) was first identified in 
the Western world in 1981 [1]. Since then, AIDS has been increasingly 
wide spreading, and its rapid worldwide dissemination brought about 
by modern mass tourism. In many developing countries, infection rates 
are increasing exponentially, despite many efforts to educate and assist 
populations in adopting a safer lifestyle. Human immunodeficiency virus 
(HIV) is the causative agent for AIDS which is continuously evolving and 
rapidly spreading throughout the world as a global infection. HIV is a 
member of lentivirus genus, which belongs to retrovirus family and is 
a single-stranded, positive-sense, enveloped RNA virus [2]. The HIV 
infection targets the monocytes expressing surface CD4 receptors and 
produces the profound defects in cell-mediated immunity [3]. Overtime 
infection leads to rigorous depletion of CD4 T-lymphocytes (T-cells), 
resulting in opportunistic infections such as tuberculosis, fungal, viral, 
protozoal, and neoplastic diseases and ultimately death [4]. Reverse 
transcriptase (RT), integrase, and protease are the three enzymes which 
are used as drug targets for the HIV treatment [2]. The RT of the HIV 
virus type 1 (HIV-1) has been well known as an important viral target 
for the discovery and development of anti-HIV therapeutic agents. 
Accordingly, two functionally distinct classes of HIV-1 RT inhibitors 
(nucleoside and non-nucleoside) have been developed and are being 
used clinically [5].
Highly active antiretroviral therapy (HAART) is the standard of 
care for AIDS patients. The majority of HIV-infected individuals are 
currently taking RT inhibitors as a critical part of HAART. The HAART 
has decreased the number of AIDS cases significantly [6]. However, 
HAART is not able to eradicate HIV-1 from patients absolutely. On the 
other hand, the toxicity of current available anti-HIV drugs makes it 
difficult to retain patients’ observance to antiretroviral therapy [7]. 
The predictable appearance of drug-resistant mutants, especially 
multidrug-resistant mutants, in response to antiretroviral therapies 
makes things worse [8]. The rates of success of HAART are predicated to 
decrease gradually with the increase in the emergence of drug-resistant 
strains. Therefore, a continuous development of novel anti-HIV agents 
which can efficiently restrain the existing drug-resistant viral strains is 
the call of the day.
Chemically, isatin may be characterized as the lactam of o-aminobenzoyl 
formic acid. Isatin is an endogenous compound identified in humans 
and rat tissues for the 1st time in 1988 [9,10]. Isatins are an important 
group of heterocyclic compounds due to the importance of indole 
backbone which is biologically active and of significant importance in 
medicinal chemistry.
Isatin (1 H-indole-2,3-dione), an endogenous compound identified in 
many organisms, shows a wide range of biological activities [11,12]. The 
isatin pharmacophore has attracted and still attracts much attention 
from medicinal chemists because of its structural resemblance to 
various moieties present in vitamins, proteins, and nucleic acids. From 
worldwide reported literature, the various isatin analogs are known 
to possess a range of biological properties, including antibacterial and 
antifungal [13-17], antiviral [18-20], anti-HIV [21,22], antiglycation [23], 
anticonvulsant, sedative-hypnotic [24,25], diuretic [26], anti-Alzheimer’s 
activity [27], and anti-inflammatory [28] activities. Among the 
structurally diverse NNRTIs, isatin scaffolds have demonstrated high 
potency against HIV-1 drug-resistant strains [29]. Thus, isatin appears 
as an ideal moiety for the development of anti-HIV agents for AIDS 
treatment which suppresses HIV replication and also possesses broad-
spectrum chemotherapeutic properties [14,30-33]. In view of the above 
details, we wish to report the synthesis and evaluation of novel isatin 
analogs, as promising anti-HIV agents.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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METHODS
All the chemicals and solvents for synthesis were purchased from 
Sigma, Spectrochem. Unless otherwise mentioned, the solvents were 
used without purification. Reactions were monitored by TLC on pre-
coated silica gel plates (Kieselgel 60 F 254, Merck), and the spots were 
detected under UV light (254 nm). Melting points were determined 
using OptimeltTM (Stanford Research Systems, Sunnyvale, CA 94089) by 
capillary method and are uncorrected. 1H nuclear magnetic resonance 
(NMR) spectra were recorded on Varian 400 MHz instrument DMSO-d6 
as a solvent. Chemical shifts are reported in parts per million (d) 
downfield with respect to tetramethylsilane (TMS) as internal 
standard. Spin multiplicities are given as s (singlet), d (doublet), t 
(triplet), and m (multiplet). Coupling constants (J) are given in hertz. 13C 
NMR spectra were recorded on a Bruker advance Spectrophotometer 
100 MHz using CDCl3 as a solvent. Mass spectra were recorded by 
the ESI-MS electrospray ionization technique. Elemental analysis was 
performed on a Vario Micro cube CHNS analyzer of elementar, and 
the values were within the acceptable ±0.4 % limit of the calculated 
values. (N-2 (2-Hydroxyothyl) piperazine-N’-(2-ethanesufonic 
acid), (N, N’-Dimethylformamine) (DMF), (3,(4,5-dimethylthiazol-
2-yl) -2,5-diphenyl tetrazolium bromide) (MTT), penicillin, 
Streptomycin sulfate, and glutamine were purchased from Sigma; 
2-(2-Mercaptoethanol) was purchased from Bio-Rad. RPMI-1640 and 
fetal bovine serum (FBS) were purchased from Gibco. In silico studies 
were carried out using absorption, distribution, metabolism, and 
elimination (ADME) software Maestro-8.5 (Schrodinger LLC) [34].
General procedure for synthesis of intermediates 3-(4-arylimino) 
1, 3-dihydro-indol-2-one (1ia-1ib) [17,35,36]
Equimolar quantities of isatin (0.004 mole) and the substituted 
aniline (0.004 mole) were dissolved in 10–15 mL of warm ethanol 
in the presence of 2–3 drops of glacial acetic acid and refluxed for 
2–3 h. After standing for approximately 24 h at room temperature, the 
crystalline yellow product was obtained (1ia-1ib), which was separated 
by filtration, further vacuum dried, and recrystallized from ethanol 
[17,35,36].
General procedure for preparation of 3-chloro-N-phenyl 
propanamide derivatives (2ia-2ih) [37]
Substituted aniline (3.01 mL, 0.033 mole) was dissolved in 12.5 ml 
glacial acetic acid. 3-chloropropionyl chloride (3.56 mL, 0.037 mole) 
was added drop wise to this solution while cooling in ice bath. The 
reaction mixture was stirred in ice-bath for 1 h and then stirred for 
2 h in room temperature. Next, the mixture was poured into saturated 
sodium acetate solution. The precipitate was filtered, washed with cold 
water, and recrystallized from ethanol:water mixture (2ia-2ih).
General preparation of synthesis of 3-(2-oxo-3-(arylimino) 
indolin-1-yl)-N-arylpropanamide (3a-3p)
To the appropriate Schiff bases of isatin (10 mmol) in 8–10 mL of 
anhydrous DMF, K2CO3 (15 mmol) was added and stirred at room 
temperature for 1 h. After completion of 1 h, the solution turned red 
brown in color. Appropriate propranamide (10 mmol) and KI (2 mmol) 
were then added to this solution drop wise and heated at 60°C for 
3–12 h. After conforming the end of reaction by TLC (EtAc:Hxn, 40:60), 
the mixture was poured into ice cold water. Precipitated crude product 
was filtered and washed thoroughly with cold water (3×200 mL). 
Compounds were recrystallized from ethanol water mixture.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-phenylpropa 
namide (3a)
Yield: 66 %, mp: 183–185°C, IR (KBr, cm−1): 3316 (NH stretching), 
3141, 3088 (Ar-CH stretching), 1745, 1673 (C=O stretching), 1607 
(C=N stretching). 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.736 (t, 
2H, J=7.2, 6.4 Hz, -CH2-), 4.049 (t, 2H, J=7.2, 6.8, -CH2-), 6.405 (d, 1H, 
J=7.2 Hz, Ar-H), 6.828 (t,1H, J=8, 6.8 Hz, Ar-H), 6.957–6.981 (m, 
1H, Ar-H), 7.012–7.049 (m, 1H, Ar-H), 7.099–7.128 (m, 1H, Ar-H), 
7.207–7.332 (m,4H, Ar-H), 7.425-7.467 (m, 1H, Ar-H), 7.482-7.549 
(t, 3H, Ar-H),10.044(s, 1H,-NH-). MS (ESI) m/z=404.0 (M+1)+; calcd 
for,C23H18ClN3O2: 403.86. Elemental Analysis: Calcd C, 68.40; H, 4.49; N, 
10.40; Found: C, 68.45; H, 4.50; N, 10.42.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-o-tolylpro 
panamide (3b)
Yield: 70 %, mp:140–142°C, IR (KBr, cm−1): 3247 (NH stretching), 
3054,2960 (Ar-CH stretching), 1744, 1708 (C=O stretching), 1601 (C=N 
stretching), 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.109 (s, 3H, -CH3), 
2.759 (t, 2H, J=6.8, 6.8 Hz, -CH2-), 4.061 (t, 2H, J=7.2, 6.4 Hz, -CH2-), 6.418 
(d, 1H, J=7.2 Hz, Ar-H), 6.842 (t,1H, J=7.6, 7.6 Hz, Ar-H), 6.938–6.975 
(m, 1H, Ar-H), 7.041–7.258 (m, 5H, Ar-H), 7.297–7.347 (m, 2H, Ar-H), 
7.436–7.558 (m, 2H, Ar-H), 9.430 (s,1H,-NH). 13C NMR (100 MHz, δ, ppm, 
CDCl3):17.87, 35.40,37.25,110.62,115.55,116.07,118.05,123.14,123.8
6,125.45,125.89,126.45,126.83,130.72, 130.81, 135.02,135.36,147.37, 
158.44,168.53. MS (ESI) m/z=418.0 (M+1)+; calcd for, C24H20ClN3O2: 
417.89, Elemental analysis: Calcd C, 68.98; H, 4.82; N, 10.06; Found: C, 
68.95; H, 4.85; N, 10.10.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-p-tolylpro 
panamide (3c)
Yield: 60 %, mp: 148–150°C, IR (KBr, cm−1): 3312 (N–H stretching), 
3190, 2933 (Ar–CH stretching), 1734, 1690 (C=O stretching), 1608 (C=N 
stretching),1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.235 (s, 3H, -CH3), 
2.710 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 4.037 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 
6.401 (d, 1H, J=7.6 Hz, Ar-H), 6.825 (t,1H, J=8, 7.6 Hz, Ar-H), 6.968 (d, 
1H, J=9.2 Hz, Ar-H), 7.062-7.126 (m, 3H, Ar-H), 7.231 (d, 1H, J=8.4 Hz, 
Ar-H), 7.322 (d, 1H, J=8 Hz, Ar-H), 7.377–7.443 (m, 3H, Ar-H), 7.463–
7.521 (m, 1H, Ar-H), 9.952 (s, 1H,-NH-). MS (ESI) m/z=418.0 (M+1)+; 
calcd for, C24H20ClN3O2: 417.89. Elemental analysis: Calcd C, 68.98; H, 
4.82; N, 10.06; Found: C, 69.01; H, 4.84; N, 10.09.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-(3-methoxy 
phenyl) propanamide (3d)
Yield: 59%, mp:120–122°C, IR (KBr, cm−1): 3310 (N–H stretching), 
3158,3104 (Ar–CH stretching), 1733, 1677 (C=O stretching), 1603 (C=N 
stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.630 (t, 2H, J=7.2, 
6.8 Hz, -CH2-), 3.692 (s,3H, -OCH3), 4.022 (t, 2H, J=6.8, 6.8 Hz, -CH2-), 6.384 
(d, 1H, J=6.8 Hz, Ar-H), 6.584–6.611 (m,1H, Ar-H), 6.809 (t, 1H, J=8, 6.8 
Hz, Ar-H), 6.916-6.963 (m, 1H, Ar-H), 7.019–7.106 (m, 2H, Ar-H), 7.112-
7.176 (m, 1H, Ar-H), 7.187-7.291 (m, 2H, Ar-H), 7.301 (d, 1H, J=8 Hz, Ar-H), 
7.407-7.629 (m, 2H, Ar-H), 10.017 (s, 1H,-NH-). MS (ESI) m/z=434.0 
(M+1)+; calcd for, C24H20ClN3O3: 433.89. Elemental analysis: Calcd C, 
66.44; H, 4.65; N, 9.68; Found: C, 66.48; H, 4.61; N, 9.70
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-(4-methoxy 
phenyl) propanamide (3e)
Yield: 73 %, mp: 192–194°C. IR (KBr, cm−1): 3298 (N–H stretching), 
3057, 2955 (Ar–CH stretching), 1732, 1665(C=O stretching), 1603 (C=N 
stretching). 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.691 (t, 2H, J=7.2, 
6.8 Hz, -CH2-), 3.708 (s,3H, -OCH3), 4.037 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 
6.405 (d, 1H, J=7.2 Hz, Ar-H), 6.809–6.868 (m,3H, Ar-H), 6.969 (d, 1H, 
J=9.2 Hz, Ar-H), 7.098–7.238 (m, 2H, Ar-H), 7.325 (d, 1H, J=8 Hz, Ar-H), 
7.393–7.523 (m, 4H, Ar-H), 9.904 (s, 1H,-NH-). MS (ESI) m/z=434.0 
(M+1)+; calcd for, C24H20ClN3O3: 433.89. Elemental analysis: Calcd C, 
66.44; H, 4.65; N, 9.68; Found: C, 66.41; H, 4.69; N, 9.72.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-(2,4-dimethy 
lphenyl) propanamide (3f)
Yield: 69 %, mp: 209–211°C. IR (KBr, cm−1): 3272 (N–H stretching), 
3063, 3030 (Ar–CH stretching), 1744,1654 (C=O stretching), 1606 (C=N 
stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.205 (s, 3H, -CH3), 
2.225 (s, 3H, -CH3), 2.728 (t, 2H, J=7.2, 6.4 Hz, -CH2-), 4.048 (t, 2H, J=7.2, 
6.4 Hz, -CH2-), 6.414 (d, 1H, J=7.6 Hz, Ar-H), 6.840 (t,1H, J=7.6, 7.2 Hz, 
Ar-H), 6.916–6.980 (m, 2H, Ar-H), 7.096 (t, 1H, J=6.8, 2 Hz, Ar-H), 
7.138–7.219 (m, 3H, Ar-H), 7.317–7.347 (m, 1H, Ar-H), 7.432–7.531 
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(m, 2H, Ar-H), 9.354 (s, 1H,-NH-). MS (ESI) m/z=432.0 (M+1)+; calcd 
for, C25H22ClN3O2: 431.91. Elemental analysis: Calcd C, 69.52; H, 5.13; N, 
9.73; Found: C, 69.55; H, 5.17; N, 9.75.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-(2,5-dimethyl 
phenyl) propanamide (3g)
Yield: 77 %, mp: 193–195°C. IR (KBr, cm−1): 3280 (N–H stretching), 
3040, 3026 (Ar–CH stretching), 1734, 1665 (C=O stretching), 1601 (C=N 
stretching). 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.050 (s, 3H, -CH3), 
2.211 (s, 3H, -CH3), 2.740 (t, 2H, J=7.2, 6.4 Hz, -CH2-), 4.053 (t, 2H, J=6.8, 
6.8 Hz, -CH2-), 6.419 (d, 1H, J=7.2 Hz, Ar-H), 6.825–6.880 (m,2H, Ar-H), 
6.960 (d, 1H, J=8 Hz, Ar-H), 7.014–7.104 (m, 3H, Ar-H), 7.127–7.218 (m, 
1H, Ar-H), 7.332 (d, 1H, J=8.4 Hz, Ar-H), 7.454 (t,1H, J=8, 7.2 Hz, -Ar-
H), 7.492–7.555 (m, 1H, Ar-H), 9.374 (s, 1H,-NH-). MS (ESI) m/z=432.0 
(M+1)+; calcd for, C25H22ClN3O2: 431.91. Elemental analysis: Calcd C, 
69.52; H, 5.13; N, 9.73; Found: C, 69.55; H, 5.17; N, 9.69.
3-(3-(3-chlorophenylimino)-2-oxoindolin-1-yl)-N-(3,4-dimethyl 
phenyl) propanamide (3h)
Yield: 80 %, mp: 155–157°C. IR (KBr, cm−1): 3271 (N–H stretching), 
3056, 2932 (Ar–CH stretching), 1732, 1683(C=O stretching), 1609 
(C=N stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.126 
(s, 6H, merged 2× -CH3), 2.681 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 4.013 (t, 
2H, J=7.2, 6.8 Hz, -CH2-), 6.383 (d, 1H, J=7.6 Hz, Ar-H), 6.809 (t,1H, 
J=8,7.2 Hz, Ar-H), 6.949 (d, 1H, J=8.8 Hz, Ar-H), 6.984–7.014 (m, 1H, Ar-
H), 7.073–7.096 (m,1H, Ar-H), 7.110–7.176 (m, 1H, Ar-H), 7.198–7.330 
(m,3H, -Ar-H), 7.406–7.532 (m, 2H, Ar-H), 9.864 (s, 1H,-NH-). MS (ESI) 
m/z=432.0 (M+1)+; calcd for, C25H22ClN3O2: 431.91. Elemental analysis: 
Calcd C, 69.52; H, 5.13; N, 9.73; Found: C, 69.54; H, 5.16; N, 9.70.
3-(3-(4-chlorophenylimino)-2-oxoindolin-1-yl)-N-phenyl 
propanamide (3i)
Yield: 71%, mp: 187–189°C. IR (KBr, cm−1): 3322 (N–H stretching), 
3184, 3067 (Ar–CH stretching), 1749, 1687 (C=O stretching). 1602 
(C=N stretching), 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.732 (t, 2H, 
J=7.2, 6.8 Hz, -CH2-), 4.047 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 6.483 (d, 1H, 
J=8 Hz, Ar-H), 6.829 (t,1H, J=7.6,7.2 Hz, Ar-H), 7.039 (d, 3H, J=8.8 Hz, Ar-
H), 7.219–7.356 (m,4H, Ar-H), 7.436 (t,1H, J=8, 7.6 Hz, -Ar-H), 7.531 (d, 
3H, J=8.8 Hz, Ar-H), 10.040 (s, 1H,-NH-). MS (ESI) m/z=404.0 (M+1)+; 
calcd for,C23H18ClN3O2: 403.86. Elemental analysis: Calcd C, 68.40; H, 
4.49; N, 10.40; Found: C, 68.42; H, 4.52; N, 10.37.
3 - ( 3 - ( 4 - ch l o ro p h e nyl i m i n o ) - 2 - oxo i n d o l i n - 1 - y l ) - N - o -
tolylpropanamide (3j)
Yield: 49 %, mp: 200–202°C, IR (KBr, cm−1): 3252 (N–H stretching), 
3224, 3101 (Ar–CH stretching), 1724,1670 (C=O stretching), 1604 (C=N 
stretching),1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.102 (s, 3H, -CH3), 
2.755 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 4.059 (t, 2H, J=7.2, 6.4 Hz, -CH2-), 6.496 
(d, 1H, J=7.2 Hz, Ar-H), 6.845 (t,1H, J=7.6, 7.2 Hz, Ar-H), 7.022–7.074 
(m, 2H, Ar-H), 7.126–7.256 (m, 3H, Ar-H), 7.298 (d, 1H, J=8 Hz, Ar-H), 
7.364 (d, 1H, J=8 Hz, Ar-H), 7.447 (t, 1H, J=8, 6.8 Hz, Ar-H),7.539(d, 2H, 
J=8.4 Hz, Ar-H), 9.426 (s, 1H,-NH-). MS (ESI) m/z=418.0 (M+1)+; calcd 
for, C24H20ClN3O2: 417.89. Elemental analysis: Calcd C, 68.98; H, 4.82; N, 
10.06; Found: C, 68.95; H, 4.85; N, 10.08.
3 - ( 3 - ( 4 - ch l o ro p h e nyl i m i n o ) - 2 - oxo i n d o l i n - 1 - y l ) - N - p -
tolylpropanamide (3k)
Yield: 64%, mp: 193–195°C, IR (KBr, cm−1): 3304 (N–H stretching), 
3158, 2940 (Ar–CH stretching), 1747, 1678 (C=O stretching), 1601 (C=N 
stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.235 (s, 3H, -CH3), 
2.708 (t, 2H, J=7.2, 6.4 Hz, -CH2-), 4.037 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 6.481 
(d, 1H, J=7.6 Hz, Ar-H), 6.829 (t,1H, J=7.6, 7.2 Hz, Ar-H), 7.028–7.193 
(m, 4H, Ar-H), 7.222 (d, 1H, J=7.6 Hz, Ar-H), 7.335-7.455 (m, 3H, Ar-
H),7.531(d, 2H, J=8.8 Hz, Ar-H), 9.951 (s, 1H,-NH-). MS (ESI) m/z=418.0 
(M+1)+; calcd for, C24H20ClN3O2: 417.89. Elemental analysis: Calcd C, 
68.98; H, 4.82; N, 10.06; Found: C, 68.95; H, 4.85; N, 10.09.
3-(3-(4-chlorophenyl imino)-2-oxoindol in-1-yl)-N-(3-
methoxyphenyl) propanamide (3l)
Yield: 59 %, mp: 164–166°C, IR (KBr, cm−1): 3310 (N–H stretching), 
3210, 3068 (Ar–CH stretching), 1743, 1690 (C=O stretching), 1602 (C=N 
stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.703 (t, 2H, J=7.2, 
6.8 Hz, -CH2-), 3.691 (s,3H, -OCH3), 4.021 (t, 2H, J=6.8, 6.8 Hz, -CH2-), 
6.464 (d, 1H, J=7.6 Hz, Ar-H), 6.599 (d,1H, J=8 Hz, Ar-H), 6.811 (t, 1H, 
J=7.6, 7.6 Hz, Ar-H), 7.011–7.106 (m, 3H, Ar-H), 7.144–7.214 (m, 2H, 
Ar-H), 7.322 (d, 1H, J=8.8 Hz, Ar-H), 7.398–7.440 (m, 1H, Ar-H), 7.500–
7.543 (m, 2H, Ar-H),10.018 (s, 1H,-NH-). MS (ESI) m/z=434.0 (M+1)+; 
calcd for, C24H20ClN3O3: 433.89. Elemental analysis: Calcd C, 66.44; H, 
4.65; N, 9.68; Found: C, 66.48; H, 4.68; N, 9.70.
3-(3-(4-chlorophenyl imino)-2-oxoindol in-1-yl)-N-(4-
methoxyphenyl) propanamide (3m)
Yield: 69%, mp: 225–227°C, IR (KBr, cm−1): 3281 (N–H stretching), 
3064, 3022 (Ar–CH stretching), 1747,1685 (C=O stretching), 1601 (C=N 
stretching),1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.686 (t, 2H, J=6.8, 
6.8 Hz, -CH2-), 3.706 (s,3H, -OCH3), 4.035 (t, 2H, J=7.2, 6.8 Hz, -CH2-), 
6.482 (d, 1H, J=8 Hz, Ar-H), 6.811–6.866 (m,3H, Ar-H), 7.039 (d, 2H, 
J=8.8 Hz, Ar-H), 7.217 (d, 1H, J=8 Hz, Ar-H), 7.395–7.454 (m, 3H, Ar-
H), 7.531 (d, 2H, J=8.4 Hz, Ar-H), 9.9 (s, 1H,-NH-). MS (ESI) m/z=434.0 
(M+1)+; calcd for, C24H20ClN3O3: 433.89. Elemental analysis: Calcd C, 
66.44; H, 4.65; N, 9.68; Found: C, 66.47; H, 4.61; N, 9.71.
3 - ( 3 - ( 4 - c h l o r o p h e n y l i m i n o ) - 2 - o x o i n d o l i n - 1 - y l ) - N -
(2,4dimethylphenyl) propanamide (3n)
Yield: 66 %, mp: 239–241°C, IR (KBr, cm−1): 3282, (N–H stretching), 
3056, 2960 (Ar–CH stretching), 1738,1678 (C=O stretching), 1608 (C=N 
stretching), 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.051 (s, 3H, -CH3), 
2.225 (s, 3H, -CH3), 2.727 (t, 2H, J=6.8, 6.8 Hz, -CH2-), 4.047 (t, 2H, J=6.8, 
6.8 Hz, -CH2-), 6.493(d, 1H, J=7.6 Hz, Ar-H), 6.844 (t,1H, J=8,7.6 Hz, Ar-
H), 6.924 (d,1H, J=7.2 Hz, Ar-H),), 6.977(s,1H, Ar-H), 7.021–7.059 (m, 
2H, Ar-H), 7.142 (d, 1H, J=8 Hz, Ar-H), 7.2 (d, 1H, J=8 Hz, Ar-H), 7.364 
(d,1H, J=8.8 Hz, -Ar-H), 7.444 (t, 1H, J=8, 8 Hz, Ar-H), 7.547 (t, 2H, J=7.2. 
1.6 Hz, Ar-H), 9.352 (s, 1H,-NH-). MS (ESI) m/z=432.0 (M+1)+; calcd for, 
C25H22ClN3O2: 431.91, Elemental Analysis: Calcd C, 69.52; H, 5.13; N, 
9.73; Found: C, 69.55; H, 5.17; N, 9.70.
3-(3-(4-chlorophenylimino)-2-oxoindolin-1-yl)-N-(2,5-dimethyl 
phenyl) propanamide (3o)
Yield: 73 %, mp: 260–262°C, IR (KBr, cm−1): 3264 (N–H stretching), 
3061, 3041 (Ar–CH stretching), 1730, 1673 (C=O stretching), 1606 
(C=N stretching).1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.042 (s, 
3H, -CH3), 2.210 (s, 3H,-CH3), 2.737 (t, 2H, J=6.8, 6.4 Hz, -CH2-), 4.051 (t, 
2H, J=7.2, 6.8 Hz, -CH2-), 6.497 (d, 1H, J=7.2 Hz, Ar-H), 6.865 (t,2H, J=7.2. 
5.6 Hz, Ar-H), 7.043 (t,3H, J=11.2, 8.8 Hz, Ar-H),), 7.20 (d,1H, J=8 Hz, 
Ar-H), 7.36 (d, 1H, J=8 Hz, Ar-H), 7.437 (d, 1H, J=7.6 Hz, Ar-H), 7.541 (d, 
2H, J=8 Hz, Ar-H), 9.371 (s, 1H,-NH-). MS (ESI) m/z=432.1 (M+1)+; calcd 
for, C25H22ClN3O2: 431.91, Elemental Analysis: Calcd C, 69.52; H, 5.13; N, 
9.73; Found: C, 69.50; H, 5.18; N, 9.79.
3-(3-(4-chlorophenylimino)-2-oxoindolin-1-yl)-N-(3,4-
dimethylphenyl) propanamide (3p)
Yield: 53 %, mp: 208–210°C, IR (KBr, cm−1): 3290 (NH stretching), 3062, 
2939 (Ar–CH stretching), 1740, 1673 (C=O stretching), 1601 (C=N 
stretching). 1H NMR (400 MHz, δ, ppm, DMSO-d6): 2.125 (s, 3H, -CH3), 
2.144 (s, 3H, -CH3), 2.679 (t, 2H, J=6.8, 6.8 Hz, -CH2-), 4.011 (t, 2H, J=6.8, 
6.8 Hz, -CH2-), 6.464 (d, 1H, J=8 Hz, Ar-H), 6.810 (t,1H, J=7.6, 7.2 Hz, Ar-
H), 7.009 (t,3H, J=8.4, 7.2 Hz, Ar-H),), 7.190–7.274 (m,2H, Ar-H), 7.321 
(d, 1H, J=8.4 Hz, Ar-H), 7.419 (t, 1H, J=7.2, 7.2 Hz, Ar-H), 7.51 (d, 2H, 
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148.38, 154.82, 163.80, 168.44, 168.4, MS (ESI) m/z=432.1 (M+1)+; 
calcd for, C25H22ClN3O2: 431.91. Elemental Analysis: Calcd C, 69.52; H, 
5.13; N, 9.73; Found: C, 69.55; H, 5.14; N, 9.77.
Cells and viruses
C8166, H9 cells, and HIV-1IIIB were kindly donated by the Medical 
Research Council, AIDS Regent Project, UK. The cells were maintained 
at 37°C in 5% CO2 in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FBS) (Gibco). HIV-1IIIB was prepared from 
the supernatants of H9/HIV-1IIIB cells. The 50% HIV-1 tissue culture 
infectious dose (TCID50) in C8166 cells was determined and calculated 
by Reed and Muench method. Virus stocks were stored in small aliquots 
at −70°C. The titer of virus stock was 1.0×108 TCID50/mL [38].
Cytotoxicity assay
The cellular toxicity of compounds on C8166 was assessed by MTT 
colorimetric assay [39]. Briefly, 100 μl of 4×105 cells was plated into 
96-well plates, and 100 μl of various concentrations of compounds 
was added and incubated at 37°C in a humidified atmosphere of 5% 
CO2 for 72 h. Discard 100 μL supernatant, MTT reagent was added and 
incubated for 4 h, and 100 μl of 50% DMF-15% SDS was added. After 
the formazan was dissolved completely, the plates were analyzed by a 
Bio-Tek ELx 800 ELISA reader at 570 nm/630 nm. CC50 was calculated.
Inhibition of syncytia formation
The inhibitory effect of samples on acute HIV-1 infection was measured 
by the syncytia formation assay. In the presence or absence of various 
concentrations of samples, 4×104 C8166 cells were infected with HIV-1 
at a multiplicity of infection of 0.04 and cultured in 96-well plates at 
37°C in 5% CO2 for 3 days. AZT was used as a positive control. At 3 days’ 
post-infection, cytopathic effect (CPE) was measured by counting the 
number of syncytia (multinucleated giant cell) in each well of 96-well 
plates under an inverted microscope [40]. The inhibitory percentage 
of syncytia formation was calculated by the percentage of syncytia 
number in treated sample compared to that in infected control. EC50 
was calculated.
According to the method described by Reed and Muench [41], CC50 and 
EC50 were determined from dose-response curve. TI of anti-HIV activity 
is CC50/EC50.
Cell viability (% of control)=(ODtest-ODblk)/(ODctrl-ODblk)×100
CPE inhibition (%)=(1-CPEtest/CPEctrl)×100
Computational studies
In silico ADME evaluation
In silico ADME evaluation of compounds was performed by ADME 
software QikProp v 3.0 [42]. Structures of the compounds were 
saved in the mol format using Chem Office software. Then, mol files 
of compounds were uploaded into the ADME predictor software for 
further evaluation. All descriptors were estimated at pH 7.4
RESULTS AND DISCUSSION
Chemistry
A library of 16 isatin analogs (3a-3p) was synthesized following the 
reaction outlined in Scheme 1. The synthesis of the title compounds 
was realized in 3 steps.
First, 1, 3-dihydro-indol-2-one (1ia-1ib) was synthesized, following the 
method reported for the synthesis of isatin [17,35,36]. For this, isatin (1) 
and substituted anilines were dissolved in warm ethanol in the presence 
of 2–3 drops of glacial acetic acid and refluxed for 2–3 h. After standing 
for approximately 24 h at room temperature (r.t), product was obtained. 
Next, the substituted anilines and 3-chloropropionyl chloride (2) were 
reacted in the presence of glacial acetic acid in ice cold condition leading 
to the formation of chloro propionamides (2ia-2ih) [36,37]. Then, the 
chloro propranamides (2ia-2ih) were treated with Schiff bases of isatin 
(1ia-1ib) to yield the title compounds (3a-3p) [Scheme 1].
The1H NMR spectra of the title compounds (3a-3p) were recorded 
in DMSO-d6 solution which entirely concorded with the predictable 
resonance signals in terms of chemical shifts and integrations [36]. 1H 
NMR spectra of the title compounds (3a-3p) showed a broad singlet of 1 
proton assigned to NH proton at δ 9.00–10.82. Depending on the nature 
of the substituent’s and substitution patterns on the N-phenyl ring, 
the aromatic protons of certain compounds (3a-3p) were observed in 
distinct chemical shifts with expected splitting patterns as doublets, 
triplets, or multiplets integrating more than one proton due to the close 
chemical shifts ranging from δ 6.365 to 7.582. In the aliphatic region, 
a broad singlet of four protons (two protons for each –CH2) assigned 
to the methylenic proton of N-CH2-CH2-CO at range δ 2.568–4.676 was 
observed for the compounds (3a-3p). A broad singlet of three protons 
assigned to methoxy protons of OCH3 at δ 3.706–3.722 was observed for 
the substituents at the N -phenyl ring of the compounds 3d, 3e, 3l, and 
3m, respectively. A broad singlet of three protons assigned to methyl 
protons of -CH3 at δ 1.993–2.286 was observed for the substituents at 
the N -phenyl ring of the compounds 3b, 3c, 3f, 3g, 3h, 3j, 3k, 3n, 3o, 
and 3p. The NMR data of the title compounds (3a-3p) are summarized 
in experimental sections. In13C NMR spectra, aromatic carbons were 
observed in the region of 112.88–161.28 ppm and aliphatic carbon was 
observed (-CH3) in the region of 17.22–21.11 ppm. The characteristic 
carbon for C=O was observed in the region of 164.81–164.00 ppm 
and –CH2 was observed 35.22–37.68 ppm. The structural confirmations 
of these compounds (3a-3p) were determined using ESI-MS.
Biological activity
The novel isatin analogs (3a-3p) were tested for their cytotoxicities 
and anti-HIV-1 activities in C8166 cells infected by the HIV-1IIIB. The 
activity data were interpreted in CC50 values (cytotoxic concentration), 
EC50 (effective concentration), and TI (therapeutic index, given by the 
CC50/EC50 ratio). The results are summarized in Table 1 and compared 
to zidovudine (AZT) as reference drugs. The experimental results 
indicated that most of the newly synthesized compounds showed 
inhibitory activity against HIV-1 RT and prevented the CPE of HIV-1IIIB at 
uM concentrations and in some cases had very low cytotoxicity against 
MT-4 cells, thus resulting in good TI.
ADME properties in silico
Modern drug development procedure using computers involves 
building a 3D virtual compound library (database) for virtual screening. 
Some libraries consist of compounds with activities against several 
diseases, for example, ZINC database while others are activity focused 
library, for example, naturally occurring plant-based anticancer 
compound activity-target database [43-45]. Before any serious time-
consuming analysis is performed, the library is usually filtered to 
eliminate unworthy molecules through a concept referred to as REOS – 
“Rapid Elimination of Swill.” REOS aids to identify molecules with poor 
ADME properties. REOS is justified by the fact that many drugs fail to 
make it to market, after many resources have been invested, because of 
poor ADME performance [46].
The principal goal of the in silico calculation of ADME properties of 
compounds is the prediction of their in vivo biokinetics as potential 
drugs [47,48]. ADME Predictor QikProp v 3.0 was applied to predict 
ADME properties of the compounds under consideration [49]. An oral 
administration is a commonly used route for drugs and a required 
Scheme 1: Synthetic route for compounds 3a-3p
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one for new agents. Absorption of drugs after oral administration 
is a very complicated process, and a number of parameters for its 
prediction are used. Relatively simple parameters are molecular 
weight (M) and polar surface area (PSA). They are included in the 
Lipinski’s rule of five [50]. The data presented in Table 2 show that all 
considered descriptors are in the recommended range (the number 
of unfulfilled rules=0). Two other parameters included in the Oprea’s 
criteria: The number of rotatable bonds (nRB) and PSA possess also the 
recommended values (nRB <10; PSA<120 Å) [47]. This shows that the 
compounds under consideration possess strong drug-like properties.
A more sophisticated model of absorption prediction takes into 
account the values of apparent permeability (Papp) for Madin-
Darby Canine Kidney cells. The data collected in Table 2 show that, 
for all compounds, medium permeability in the range is acceptable 
(<25 poor, >500 great) [51]. Good native water solubility (S) for all 
compounds is estimated and also acceptable range (–6.5–0.5) [52-
54]. The predicted log BB (logarithm of the brain/blood partition 
coefficient) that were both calculated. According to the data collected 
in Table 2, all studied compounds show low brain penetration (log BB 
–3.0–1.2), and they rather do not across BBB [55-57]. This implied that 
Table 1: Cytotoxicity and anti-HIV activity of newly synthesized compounds
Compound Experiment Method First time Second time
CC50 (mM) EC50 (mM) CC50 (mM) EC50 (mM) TI
3a CA MTT 26.23 — 36.08 — 2.2
ISF CPE — 12.08 — 16.09
3b CA MTT 164.11 — — — 7.4
ISF CPE — 22.06 — —
3c CA MTT 33.31 — 31.51 —  1.1-1.7
ISF CPE — 31.25 — 19.05
3d CA MTT 21.26 — — — 2.7
ISF CPE — 7.77 — —
3e CA MTT 56.25 — — — 3.1
ISF CPE — 18.09 — —
3f CA MTT 166.30 — — — 9.3
ISF CPE — 17.87 — —
3g CA MTT 29.60 — — — 2.2
ISF CPE — 13.27 — —
3h CA MTT 29.55 — — — 3.8
ISF CPE — 7.76 — —
3i CA MTT 70.19 — — — 8.2
ISF CPE —  8.52 — —
3j CA MTT 34.49 — — — 2.2
ISF CPE — 15.91 — —
3k CA MTT 74.55 — — — 3.7
ISF CPE — 20.15 — —
3l CA MTT 74.59 — 129.98 — 4.9-8.3
ISF CPE — 15.17 — 15.74
3m CA MTT 175.70 — 193.46 — 7.2-9.4
ISF CPE — 18.60 — 26.99
3n CA MTT 216.16 — 203.82 — 5.9-10.2
ISF CPE — 36.40 — 20.00
3o CA MTT >231.53 — >231.53 — >8.6
ISF CPE — 21.51 — 26.90
3p CA MTT 214.53 — — — 6.8
ISF CPE — 31.40 — —
AZT CA MTT 4830.86 — — — 5×105
ISF CPE — 0.0094 — —
Table 2: Prediction of ADME properties of newly synthesized compounds
Comp. nRB MW LogPo/w PlogS PlogBB PMDCK % HOA PSA Rule of five
3a 6 403.867 4.506 −6.257 −0.79 1150.341 100 78.784 0
3b 6 417.894 4.813 −6.618 −0.719 1362.555 100 76.728 0
3c 6 417.894 4.814 −6.827 −0.82 1150.209 100 78.786 0
3d 7 433.893 4.603 −6.431 −0.852 1206.357 100 87.038 0
3e 7 433.893 4.581 −6.413 −0.872 1149.274 100 87.078 0
3f 6 431.921 5.122 −7.189 −0.747 1363.14 100 76.727 1
3g 6 431.921 5.125 −7.198 −0.748 1363.175 100 76.73 1
3h 6 431.921 5.085 −7.248 −0.835 1149.125 100 78.784 1
3i 6 403.867 4.507 −6.258 −0.79 1151.717 100 78.782 0
3j 6 417.894 4.814 −6.62 −0.719 1362.414 100 79.732 0
3k 6 417.894 4.816 −6.832 −0.821 1151.795 100 78.781 0
3l 7 433.893 4.604 −6.432 −0.851 1207.409 100 87.042 0
3m 7 433.893 4.581 −6.414 −0.871 1150.661 100 87.074 0
3n 6 431.921 5.109 −7.09 −0.728 1381.529 100 76.518 1
3o 6 431.921 5.113 −7.1 −0.729 1381.694 100 76.521 1
3p 6 431.921 5.086 −7.249 −0.835 1150.457 100 78.779 1
ADME: Absorption, distribution, metabolism and elimination
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oral bioavailability of the all designed compounds was good and all the 
compounds (3a-3p) showed ADME properties in acceptable range.
CONCLUSION
To sum up, we have obtained and characterized a series of 1-H-indole-2, 
3-dione (Isatin) as a new group of heterocyclic compounds. They were 
prepared in the multi-step novel efficient synthesis procedure. The 
compounds displayed diverse anti-HIV activities against cell lines.
In summary, through rational design, we have generated the 16 novel 
isatin analogs (3a-3p) as inhibitors of HIV in comparison with AZT. 
Interestingly, the biological studies revealed that several isatin analogs 
showed comparable HIV inhibitory activity with low cytotoxicity. SAR 
studies suggested that mostly isatin analogs with electron-releasing 
substituents in the phenyl ring attached to the isatin nucleus by the 
linker moiety -CH2CH2CONH- showed highest therapeutic index, though 
it was much less than that of AZT.
The compounds 3f, 3i, 3m, 3n, and 3o displayed moderate anti-HIV 
activity. These results appear to confirm that the isatin moiety would be 
beneficial to improve the antiviral activity. It is worth mentioning that 
the TI values of the derivatives for inhibiting HIV are in the comparable 
ranges. Due to their excellent potency, the biological and the structural 
data would serve as a valuable guide to the further optimization of 
the anti-HIV activity of the Schiff bases of isatin family. Furthermore, 
the compounds possess strong drug-like properties and good 
pharmacokinetics as well as low toxicity is predicted for them in silico.
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